ACADIA Pharmaceuticals Inc. stock performance trend indicates that the stock price has rallied 24.81% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 16.72% . Looking at the past 52 week period, the stock price is up at 87.62% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of ACADIA Pharmaceuticals Inc. has a positive value of 7.09 compared to overall market.ACADIA Pharmaceuticals Inc. is having a Relative Strength Index of 51.38 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Stocks of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rallied by 0.81% during the past week but lost 5.47% on a 4-week basis. The company has outperformed the S&P 500 by 0.58% in the past week but underperformed the index by 6.55% in the last 4 weeks.
For the current week, the company shares have a recommendation consensus of Buy. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.37 points or 0.99% at $37.13 with 1,677,182 shares getting traded. Post opening the session at $37.33, the shares hit an intraday low of $36.95 and an intraday high of $37.75 and the price was in this range throughout the day. The company has a market cap of $4,508 million and the number of outstanding shares has been calculated to be 121,407,626 shares. The 52-week high of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is $42.49 and the 52-week low is $18.4.
Company has reported several Insider transactions to the SEC, on Feb 23, 2017, Terrence O Moore (EVP, CHIEF COMMERCIAL OFFICER) sold 7,856 shares at 39.65 per share price.On Feb 16, 2017, Glenn Baity (EVP AND GC) sold 26,365 shares at 39.65 per share price.On Feb 19, 2015, Uli Hacksell (CEO) sold 30,000 shares at 34.30 per share price.
ACADIA Pharmaceuticals Last issued its quarterly earnings results on Feb 28, 2017. The company reported $-0.65 EPS for the quarter, missing the analyst consensus estimate by $ -0.01. Analyst had a consensus of $-0.64. The company had revenue of $12.00 million for the quarter, compared to analysts expectations of $9.06 million. The companys revenue was up 70488.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.45 EPS.
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinsons disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.